Pertuzumab biosimilar - Zydus Cadila
Alternative Names: ZRC-3277Latest Information Update: 24 May 2024
At a glance
- Originator Zydus Cadila
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Dimerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III HER2 positive breast cancer
Most Recent Events
- 20 Mar 2024 Zydus Lifesciences Limited completes a phase III trials in HER2-positive breast cancer (Combination therapy, Metastatic disease, Late-stage disease, In adults, In the elderly) in India (IV) (NCT05283837)
- 20 Mar 2024 Pharmacokinetics, Efficacy, adverse events and immunogenicity data from phase-III trial in HER2-positive breast cancer presented at the 14th European Breast Cancer Conference (EBCC-2024)
- 20 Mar 2024 Zydus Lifesciences completes enrolment in phase-III trial for HER2-positive breast cancer (Combination therapy, Metastatic disease, Late-stage disease, In adults, In the elderly) in India (IV) before March 2024 (NCT05283837)